Literature DB >> 19698817

An economic comparison of female sterilization of hysteroscopic tubal occlusion with laparoscopic bilateral tubal ligation.

Dale F Kraemer1, Po-Yin Yen, Mark Nichols.   

Abstract

BACKGROUND: This study compares the expected 5-year costs for permanent sterilization in women between nonincisional hysteroscopic tubal occlusion with the Essure system performed in an office setting and laparoscopic bilateral tubal ligation (LBTL). STUDY
DESIGN: An economic decision tree is used to predict outcomes and costs to compare these two procedures from a US Medicaid perspective over a 5-year time horizon.
RESULTS: Expected costs are $2367 for Essure and $3545 for LBTL (Essure saves $1178 or 33% of LBTL costs). Sensitivity analyses show Essure has lower expected costs across all values considered. If the cost for a LBTL procedure were to decrease by 20% and the cost for Essure to increase by 20%, Essure would have still have lower expected costs.
CONCLUSION: Office-based sterilization for women using Essure can lead to substantial cost savings over 5 years compared to LBTL. This conclusion is robust to varying analytic inputs.

Entities:  

Mesh:

Year:  2009        PMID: 19698817     DOI: 10.1016/j.contraception.2009.02.010

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  7 in total

Review 1.  Techniques for the interruption of tubal patency for female sterilisation.

Authors:  Theresa A Lawrie; Regina Kulier; Juan Manuel Nardin
Journal:  Cochrane Database Syst Rev       Date:  2016-08-05

2.  What are the factors predictive of hysterosalpingogram compliance after female sterilization by the Essure procedure in a publicly insured population?

Authors:  David L Howard; Jeffrey Wall; Julie L Strickland
Journal:  Matern Child Health J       Date:  2013-12

Review 3.  Hysteroscopic tubal sterilization: a health economic literature review.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2013-10-01

4.  Efficacy, safety, and patient acceptability of the Essure™ procedure.

Authors:  Collette R Lessard; Matthew R Hopkins
Journal:  Patient Prefer Adherence       Date:  2011-04-28       Impact factor: 2.711

5.  Contraceptive failure after hysteroscopic sterilization: Analysis of clinical and demographic data from 103 unplanned pregnancies.

Authors:  E Scott Sills; Xiang Li; Christopher A Jones; Samuel H Wood
Journal:  Obstet Gynecol Sci       Date:  2015-11-16

6.  Analysis of surgeries performed after hysteroscopic sterilization as tabulated from 3,803 Essure patient experiences.

Authors:  E Scott Sills; Xiang Li; Samuel H Wood; Christopher A Jones
Journal:  Obstet Gynecol Sci       Date:  2017-05-15

7.  Management of long-term and reversible hysteroscopic sterilization: a novel device with nickel-titanium shape memory alloy.

Authors:  Bin Xu; Ke-an Zhu; Dabao Xu; Aixingzi Aili
Journal:  Reprod Biol Endocrinol       Date:  2014-07-07       Impact factor: 5.211

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.